Naltrexone, Craving, and Drinking - Full Text View

Naltrexone, Craving, and Drinking

This study has been completed.

Sponsored by:	National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by:	National Institute on Alcohol Abuse and Alcoholism (NIAAA)
ClinicalTrials.gov Identifier:	NCT00006203

Purpose

This 5-week study will examine the effects of naltrexone on alcohol craving, drinking rates, and reaction to drinking-related triggers, or cues, in participants' everyday environment and in laboratory sessions. Participants will monitor and record their daily desires to drink, environmental circumstances in which urges occur, and drinking behavior using a palm top computer. Participants will receive naltrexone or a placebo. One week after receiving medication, all participants will be asked to respond to alcohol-related cues that may or may not arouse the desire to drink.

Condition	Intervention	Phase
Alcoholism	Drug: naltrexone (Revia)	Phase IV

MedlinePlus related topics:

Alcoholism

Drug Information available for:

Naltrexone Naltrexone hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Placebo Control, Efficacy Study

Official Title:	Naltrexone, Craving, and Drinking: Ecological Assessment

Further study details as provided by National Institute on Alcohol Abuse and Alcoholism (NIAAA):

Estimated Enrollment:	186
Estimated Study Completion Date:	May 2005

Eligibility

Ages Eligible for Study:	21 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Drink at least 4 days per week with 2 heavy drinking days (more than 6 standard drinks for men, more than 5 drinks for women) per week on average during the month prior to the study.

Exclusion Criteria:

Current interest in treatment or a history of treatment for alcohol problems.
History of liver disease or current liver function tests greater than five times normal.
Opiate abuse or dependence, any opiate use two weeks before the study or a urine test screen that is positive for opiates.
Females, who are pregnant, nursing, or not using reliable birth control method.
Daily use of acetaminophen.
Living with someone who participated in this study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00006203

Locations


United States, Rhode Island
	Center for Alcohol and Addiction Studies, Brown University
	Providence, Rhode Island, United States, 02919

Sponsors and Collaborators

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

More Information

Study ID Numbers:	NIAAAMON0785011A1
First Received:	September 11, 2000
Last Updated:	October 20, 2006
ClinicalTrials.gov Identifier:	NCT00006203
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Mental Disorders

Naltrexone

Alcoholism

Substance-Related Disorders

Disorders of Environmental Origin

Alcohol-Related Disorders

Additional relevant MeSH terms:

Sensory System Agents

Therapeutic Uses

Physiological Effects of Drugs

Narcotic Antagonists

Peripheral Nervous System Agents

Central Nervous System Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on December 03, 2008